Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 1 (January)

1. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
   Haematologica, 93(1): 49-56. [Abstract] [Full-text]
2. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
   Br J Haematol, 140(2): 181-90. [Abstract] [Full-text]
3. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.
   Eur J Haematol, 80(1): 81-6. [Abstract] [Full-text]
4. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.
   Eur J Clin Invest, 38(1): 43-52. [Abstract] [Full-text]
5. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
   Cancer Chemother Pharmacol, 61(4): 713-6. [Abstract] [Full-text]
6. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
   Biochem Biophys Res Commun, 366(4): 1007-11. [Abstract] [Full-text]
7. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses.
   J Mol Med, 86(1): 17-27. [Abstract] [Full-text]
8. Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.
   Med Oncol, 25(1): 110-2. [Abstract] [Full-text]
9. Successful combined use of tranexamic Acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.
   Int J Hematol, 86(5): 403-6. [Abstract] [Full-text]
10. Conjunctival hemorrhagic events associated with imatinib mesylate.
    Int J Hematol, 86(5): 390-3. [Abstract] [Full-text]
11. Disruption of PDGFR{alpha}-initiated PI3K activation and migration of somite derivatives leads to spina bifida.
    Development, 135(3): 589-98. [Abstract] [Full-text]
12. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Int J Lab Hematol, 30(1): 68-70. [Abstract] [Full-text]
13. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate.
    J Cutan Pathol, 35(2): 197-202. [Abstract] [Full-text]
14. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
    Pediatr Blood Cancer, 50(3): 639-41. [Abstract] [Full-text]
15. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signaling.
    J Cell Mol Med. [Abstract] [Full-text]
16. The history of myeloproliferative disorders: before and after Dameshek.
    Leukemia, 22(1): 3-13. [Abstract] [Full-text]
17. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group.
    Eur J Haematol, 80(2): 160-3. [Abstract] [Full-text]
18. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
    Clin Pharmacol Ther, 83(2): 258-64. [Abstract] [Full-text]
19. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
    Leuk Lymphoma, 49(1): 19-26. [Abstract] [Full-text]
20. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
    Mol Cancer Ther, 7(1): 48-58. [Abstract] [Full-text]
21. Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function.
    Cancer Lett, 260(1): 146-54. [Abstract] [Full-text]
22. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Ann Hematol, 87(3): 183-93. [Abstract] [Full-text]
23. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
    J Cell Biochem, 103(2): 607-14. [Abstract] [Full-text]
24. Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia (February).
    Ann Pharmacother. [Abstract] [Full-text]
25. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Dermatology, 216(2): 109-17. [Abstract] [Full-text]
26. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    Am J Kidney Dis, 51(2): 298-301. [Abstract] [Full-text]
27. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis.
    Mod Pathol, 21(2): 96-104. [Abstract] [Full-text]
28. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series.
    J Clin Pathol, 61(2): 203-8. [Abstract] [Full-text]
29. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment.
    Blood, 111(3): 1039-43. [Abstract] [Full-text]
30. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
    Clin Cancer Res, 14(2): 541-8. [Abstract] [Full-text]
31. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
    Clin Cancer Res, 14(2): 352-9. [Abstract] [Full-text]
32. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
    J Cell Physiol, 215(1): 111-21. [Abstract] [Full-text]
33. Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?
    Clin Exp Immunol, 151(3): 391-8. [Abstract] [Full-text]
34. Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
    Nat Clin Pract Oncol, 5(2): 102-11. [Abstract] [Full-text]
35. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    J Clin Oncol, 26(4): 626-32. [Abstract] [Full-text]
36. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
    J Clin Oncol, 26(4): 620-5. [Abstract] [Full-text]
37. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    J Clin Oncol, 26(4): 570-6. [Abstract] [Full-text]
38. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    J Clin Oncol, 26(4): 563-9. [Abstract] [Full-text]
39. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
    PLoS Med, 5(1): e19. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.